Stock listing
NASDAQ:JSPR Jasper Therapeutics, Inc. Stock
Home listing (NASDAQ) of Jasper Therapeutics, Inc.
Follow Jasper Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:JSPR
$8.69 USD -2.06 (-19.2%)
Close on Nov 20, 2026
- Day range
- $8.47 – $12.00 USDNov 20, 2026
- Volume
- 11,716 sharesNov 20, 2026
- Market cap
- $9.64M USDAt the close on Nov 20, 2026 · price × 1.11M shares outstanding
- 52-week range
- $0.315 – $17.03 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $105,926 USDMedian day 12,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:JSPR · Home | $8.69 USD | -2.06 (-19.2%) | 11,716 | $10.95 | $12.00 | $8.47 | $10.75 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:JSPR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $8.69 | -2.06 | -19.2% | $10.95 | $12.00 | $8.47 | 11,716 | |
| $10.75 | -0.77 | -6.7% | $10.69 | $11.50 | $10.61 | 10,900 | |
| $11.52 | +1.18 | +11.4% | $10.67 | $11.86 | $10.66 | 19,300 | |
| $10.34 | -1.43 | -12.1% | $11.96 | $12.00 | $9.25 | 49,000 | |
| $11.77 | -1.91 | -14.0% | $13.67 | $14.35 | $11.77 | 23,500 | |
| $13.68 | +0.31 | +2.3% | $13.51 | $14.56 | $12.93 | 16,500 | |
| $13.37 | -1.39 | -9.4% | $14.27 | $14.99 | $13.37 | 32,400 | |
| $14.76 | +0.01 | +0.1% | $15.04 | $15.45 | $13.64 | 69,500 | |
| $14.75 | -1.62 | -9.9% | $15.24 | $15.87 | $14.09 | 47,200 | |
| $16.37 | -0.49 | -2.9% | $17.03 | $17.03 | $14.26 | 53,300 | |
| $16.86 | +2.79 | +19.8% | $12.76 | $17.00 | $12.76 | 63,400 | |
| $14.07 | -1.26 | -8.2% | $14.91 | $14.94 | $13.50 | 17,857 | |
| $15.33 | +0.93 | +6.5% | $13.98 | $15.60 | $13.20 | 26,087 | |
| $14.40 | -0.84 | -5.5% | $15.27 | $15.90 | $14.10 | 8,720 | |
| $15.24 | +14.72 | +2830.8% | $15.57 | $16.50 | $14.94 | 15,073 | |
| $0.52 | -0.012 | -2.3% | $0.516 | $0.554 | $0.511 | 13,200 | |
| $0.532 | -0.007 | -1.3% | $0.533 | $0.563 | $0.511 | 13,770 | |
| $0.539 | +0.02 | +3.9% | $0.50 | $0.548 | $0.50 | 12,373 | |
| $0.519 | +0.014 | +2.8% | $0.477 | $0.53 | $0.46 | 44,140 | |
| $0.505 | -0.005 | -1.0% | $0.51 | $0.521 | $0.495 | 13,223 | |
| $0.51 | +0.014 | +2.8% | $0.496 | $0.54 | $0.484 | 10,783 | |
| $0.496 | -0.008 | -1.6% | $0.50 | $0.515 | $0.49 | 2,410 | |
| $0.504 | +0.004 | +0.8% | $0.52 | $0.54 | $0.497 | 11,960 | |
| $0.50 | +0.023 | +4.8% | $0.478 | $0.529 | $0.477 | 12,217 | |
| $0.477 | -0.003 | -0.6% | $0.47 | $0.49 | $0.46 | 13,050 | |
| $0.48 | -0.052 | -9.8% | $0.546 | $0.55 | $0.478 | 8,187 | |
| $0.532 | +0.031 | +6.2% | $0.49 | $0.545 | $0.476 | 12,667 | |
| $0.501 | +0.005 | +1.0% | $0.501 | $0.517 | $0.46 | 20,670 | |
| $0.496 | -0.059 | -10.6% | $0.54 | $0.54 | $0.496 | 14,310 | |
| $0.555 | -0.015 | -2.6% | $0.569 | $0.577 | $0.545 | 11,193 | |
| $0.57 | +0.01 | +1.8% | $0.547 | $0.577 | $0.541 | 8,730 | |
| $0.56 | -0.01 | -1.8% | $0.563 | $0.58 | $0.54 | 12,073 | |
| $0.57 | +0.01 | +1.8% | $0.543 | $0.59 | $0.54 | 12,173 | |
| $0.56 | -0.033 | -5.6% | $0.60 | $0.60 | $0.55 | 10,930 | |
| $0.593 | +0.028 | +5.0% | $0.57 | $0.596 | $0.542 | 12,533 | |
| $0.565 | -0.033 | -5.5% | $0.60 | $0.615 | $0.563 | 7,870 | |
| $0.598 | +0.018 | +3.1% | $0.59 | $0.64 | $0.585 | 9,820 | |
| $0.58 | -0.045 | -7.2% | $0.62 | $0.655 | $0.572 | 17,950 | |
| $0.625 | -0.001 | -0.2% | $0.642 | $0.675 | $0.584 | 30,523 | |
| $0.626 | +0.017 | +2.8% | $0.606 | $0.656 | $0.60 | 8,370 | |
| $0.609 | +0.024 | +4.1% | $0.593 | $0.62 | $0.579 | 5,437 | |
| $0.585 | +0.018 | +3.2% | $0.592 | $0.592 | $0.544 | 21,140 | |
| $0.567 | -0.056 | -9.0% | $0.628 | $0.648 | $0.567 | 14,233 | |
| $0.623 | +0.02 | +3.3% | $0.629 | $0.651 | $0.606 | 10,337 | |
| $0.603 | -0.015 | -2.4% | $0.636 | $0.67 | $0.60 | 6,867 | |
| $0.618 | -0.016 | -2.5% | $0.63 | $0.65 | $0.60 | 7,427 | |
| $0.634 | +0.053 | +9.1% | $0.59 | $0.66 | $0.59 | 10,120 | |
| $0.581 | +0.011 | +1.9% | $0.577 | $0.609 | $0.56 | 16,843 | |
| $0.57 | -0.063 | -10.0% | $0.64 | $0.644 | $0.568 | 13,420 | |
| $0.633 | -0.027 | -4.1% | $0.66 | $0.668 | $0.60 | 13,477 | |
| $0.66 | -0.041 | -5.8% | $0.693 | $0.711 | $0.66 | 9,810 | |
| $0.701 | 0.00 | 0.0% | $0.69 | $0.73 | $0.69 | 6,930 | |
| $0.701 | -0.008 | -1.1% | $0.701 | $0.714 | $0.68 | 2,010 | |
| $0.709 | 0.00 | 0.0% | $0.739 | $0.74 | $0.695 | 6,330 | |
| $0.709 | +0.023 | +3.4% | $0.67 | $0.71 | $0.664 | 14,427 | |
| $0.686 | -0.019 | -2.7% | $0.693 | $0.71 | $0.653 | 12,133 | |
| $0.705 | +0.007 | +1.0% | $0.688 | $0.72 | $0.68 | 12,677 | |
| $0.698 | -0.013 | -1.8% | $0.70 | $0.711 | $0.635 | 28,473 | |
| $0.711 | +0.011 | +1.6% | $0.715 | $0.74 | $0.655 | 12,933 | |
| $0.70 | +0.001 | +0.1% | $0.71 | $0.71 | $0.66 | 8,913 | |
| $0.699 | -0.019 | -2.6% | $0.707 | $0.744 | $0.69 | 8,473 | |
| $0.718 | -0.002 | -0.3% | $0.714 | $0.721 | $0.692 | 8,203 | |
| $0.72 | -0.002 | -0.3% | $0.709 | $0.74 | $0.699 | 9,050 | |
| $0.722 | +0.006 | +0.8% | $0.73 | $0.735 | $0.674 | 11,803 | |
| $0.716 | +0.025 | +3.6% | $0.68 | $0.736 | $0.675 | 26,027 | |
| $0.691 | -0.056 | -7.5% | $0.735 | $0.76 | $0.678 | 77,870 |
Splits
1 split · NASDAQ:JSPR · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:JSPR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
Jasper Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 29 slides
Latest news
Jasper Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 16, 2026
Closed $11.77 (-14.0%) on Nov 16, 2026
Jasper Therapeutics, Inc. Announces Results of the Offer to Purchase Relating to Its Warrants
Nov 9, 2026
Closed $16.37 (-2.9%) on Nov 9, 2026
Jasper Therapeutics Announces 1-for-30 Reverse Stock Split
Nov 4, 2026
Closed $15.33 (+6.5%) on Nov 4, 2026
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
Oct 15, 2026
Closed $0.532 (+6.2%) on Oct 15, 2026
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
Oct 7, 2026
Closed $0.57 (+1.8%) on Oct 7, 2026
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
Sep 15, 2026
Closed $0.581 (+1.9%) on Sep 16, 2026
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 9, 2026
Closed $0.701 (-1.1%) on Sep 9, 2026
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 17, 2026
Closed $0.842 (+6.6%) on Aug 17, 2026
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
Jul 16, 2026
Closed $0.885 (+14.3%) on Jul 17, 2026
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
Jun 1, 2026
Closed $0.534 (-35.6%) on Jun 1, 2026
Jasper Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 17 in the last 12 months · 97 in all · newest Nov 16, 2026 · oldest 2021
- Decks
- 22 decks · latest September 2026
Where Jasper Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:JSPR · Home listing · This page | NASDAQ | United States | USD |
| BOATS:JSPR | BOATS | United States | USD |
Valuation
EV/sales −15.7× against a median of −5.9×: 3rd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$125.6M USD
- P/E
- Loss
- EV/sales
- −15.7×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 2.02
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Jasper Therapeutics, Inc. · NASDAQ:JSPR | US$9.64M | −US$125.6M | n/a | −15.7× | n/a | n/a | n/a | n/a | 2.02 |
| Ceryvyn Therapeutics Limited · ASX:CYV | US$9.96M | −US$9.91M | 0.1× | −14,971× | n/a | 0.5× | n/a | 0.0× | n/a |
| aTyr Pharma, Inc. · NASDAQ:ATYR | US$9.74M | −US$28.09M | n/a | n/a | n/a | 0.3× | n/a | 0.3× | 2.12 |
| Lisata Therapeutics, Inc. · NASDAQ:LSTA | US$9.71M | −US$273.0M | n/a | −2,730× | n/a | 1.3× | n/a | 0.0× | 0.71 |
| Purple Biotech Ltd. · TASE:PPBT | US$9.70M | US$3.73M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | n/a |
| Chemomab Therapeutics Ltd. · NASDAQ:CMMB | US$9.58M | US$4.92M | n/a | n/a | n/a | 2.6× | n/a | 0.0× | 1.04 |
| Alzinova AB · OMXSTO:ALZ | US$9.57M | US$8.34M | n/a | 17.0× | n/a | 0.6× | −484.4% | 0.0× | n/a |
| Genvor Incorporated · OTC:GNVR | US$9.47M | US$9.27M | n/a | n/a | n/a | n/a | n/a | n/a | 0.44 |
| Poxel SA · EURONEXT:POXEL | US$9.27M | US$73.95M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TScan Therapeutics, Inc. · NASDAQ:TCRX | US$9.27M | −US$30.80M | n/a | −5.9× | n/a | 0.2× | n/a | 0.9× | 1.66 |
| Rapid Dose Therapeutics Corp · CSE:DOSE | US$9.13M | US$9.12M | n/a | 5.1× | n/a | n/a | −123.1% | n/a | 0.64 |
| Median of the others | US$9.57M | US$4.33M | 0.1× | −5.9× | 0.6× | −303.7% | 0.0× | 0.88 |
Forecasts
2 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 600.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -6.90 · 2 analysts
- Revenue, year to Dec 2026
- 6M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jeet Mahal | Chief Executive Officer |
| Rick Ruiz | Vice President, Finance |
| Matthew Ros | Chief Operating Officer |
| Abby Kennedy | Vice President, Clinical Operations |
| Helen Fu | Vice President, Corporate Portfolio and Project Management |
| Lisa Pitt | Senior Vice President, Regulatory Affairs |
| Mark Camarena | Vice President, Information Technology and Facilities |
| Matt Ford | Senior Vice President, Human Resources |
| Shiguang Liu | Vice President, Clinical Development |
| Wenru Song | Executive Vice President and Head of R&D |
| Greg Keenan | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Thomas Wiggans | Chairman of the Board |
| Judith Shizuru | Board Member |
| Kurt von Emster | Board Member |
| Patrick Crutcher | Board Member |
| Svetlana Lucas | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · After close | −12.2% |
| Q2 2026 | Aug 14, 2026 · Before open | −8.5% |
| Q1 2026 | May 14, 2026 · After close | −11.4% |
| Q3 2025 | Nov 10, 2025 · Before open | 0.0% |
| Q2 2025 | Aug 13, 2025 · After close | +2.0% |
| Q1 2025 | May 12, 2025 · Before open | +4.9% |
| Q4 2024 | Feb 27, 2025 · Before open | −2.2% |
| Q3 2024 | Nov 7, 2024 · Before open | −4.3% |
| Q2 2024 | Aug 13, 2024 · Before open | +12.4% |
| Q1 2024 | May 14, 2024 · Before open | +0.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 4, 2024 · Before open | +0.9% |
| Q3 2023 | Nov 9, 2023 · Before open | −8.1% |
| Q2 2023 | Aug 11, 2023 · After close | −4.3% |
| Q1 2023 | May 12, 2023 · After close | −0.6% |
| Q4 2022 | Mar 8, 2023 · After close | −7.0% |
| Q3 2022 | Nov 10, 2022 · After close | +1.5% |
| Q2 2022 | Aug 12, 2022 · After close | −7.1% |
| Q1 2022 | May 12, 2022 · After close | +2.0% |
| Q4 2021 | Mar 18, 2022 · After close | +1.1% |
| Quarter to Sep 30, 2021 | Nov 12, 2021 · After close | +4.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 29 slides | September 2026 |
| Merger or Acquisition (July 2026) | Merger or acquisition | 30 slides | Jul 17, 2026 |
| JPM TMT Conference (January 2026) | Conference | 14 slides | Jan 8, 2026 |
| Corporate Update (January 2026) | Corporate update | 20 slides | Jan 8, 2026 |
| Corporate Update (December 2025) | Corporate update | 31 slides | Dec 2, 2025 |
| Investor Presentation (July 2025) | Investor deck | 24 slides | Jul 7, 2025 |
| Corporate Update (June 2025) | Corporate update | 19 slides | Jun 16, 2025 |
| Technical Presentation (January 2025) | Technical | 27 slides | Jan 8, 2025 |
| Technical Presentation (June 2024) | Technical | 13 slides | Jun 2, 2024 |
| EAACI Congress 2024 | Conference | 20 slides | Jun 1, 2024 |
All 22 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (March 2024) | Technical | 12 slides | March 2024 |
| ASH Annual Meeting 2023 | Conference | 16 slides | Dec 10, 2023 |
| Investor Presentation (October 2023) | Investor deck | 29 slides | Oct 10, 2023 |
| Investor Presentation (June 2023) | Investor deck | 55 slides | Jun 2, 2023 |
| Investor Presentation (January 2023) | Investor deck | 51 slides | Jan 24, 2023 |
| Investor Presentation (January 2023) | Investor deck | 37 slides | Jan 10, 2023 |
| Technical Presentation (April 2022) | Technical | 18 slides | Apr 27, 2022 |
| Investor Presentation (March 2022) | Investor deck | 8 slides | Mar 16, 2022 |
| Amplitude Healthcare Acquisition — SPAC Merger (September 2021) | SPAC merger | 33 slides | Sep 9, 2021 |
| Amplitude Healthcare Acquisition — SPAC Merger (June 2021) | SPAC merger | 36 slides | Jun 8, 2021 |
| SPAC Merger (May 2021) | SPAC merger | 20 slides | May 7, 2021 |
| SPAC Merger (May 2021) | SPAC merger | 77 slides | May 6, 2021 |
Financings
| Raise | Date |
|---|---|
| Private placement of non-voting convertible preferred stock Closed: US$132M raised · Piper Sandler & Co. +1 Dealers: Piper Sandler & Co. (lead), LifeSci Capital LLC (co-lead) Buyers: Affinity Asset Advisors, LLC (co-led the private placement); Ikarian Capital LLC (co-led the private placement); Columbia Threadneedle Investments; Sirenia Capital Management LP; Brahma Capital; Balyasny Asset Management; SilverArc Capital; Squadron Capital Management; Nazare Partners LP; Mirador Therapeutics Use of proceeds: Fund development of the combined company's pipeline through the second half of 2028 | Aug 17, 2026 |
| Public offering of common stock and warrants Closed: US$30M raised · US$2.43 a share · Warrants at US$2.92 for 48 months · TD Cowen Dealers: TD Cowen (lead) Use of proceeds: Extends cash runway through the first half of 2026 | Nov 10, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Amplitude Healthcare Acquisition Corp, a blank check company (SPAC). Priced at US$10.00 a unit on Nov 19, 2019.
- Price
- US$10.00 a unit
- Units offered
- 10,000,000 units
- Offering size
- US$100 million
- Underwriters' option
- Up to 1,500,000 more units
- Listing
- AMHCU on the Nasdaq Capital Market
- Underwriters
- BMO Capital Markets, SVB Leerink · In the order on the cover
- Units delivered
- On or about Nov 22, 2019
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Sep 13, 2019 |
| Filed publicly | Oct 25, 2019 |
| Amended 3 times | Newest Nov 14, 2019 |
| Shares registered with an exchange | Nov 18, 2019 |
| Declared effective by the SEC | Nov 19, 2019 |
| Final prospectus, with the price | Nov 21, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Nov 21, 2019 |
| CERT · Exchange's certificate of listing | Nov 20, 2019 |
| EFFECT · Notice that a registration is effective | Nov 19, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 18, 2019 |
| CORRESP · Letter to the SEC | Nov 18, 2019 |
| CORRESP · Letter to the SEC | Nov 18, 2019 |
| CORRESP · Letter to the SEC | Nov 14, 2019 |
| S-1/A · Registration statement, amended | Nov 14, 2019 |
| UPLOAD · Letter from the SEC | Nov 14, 2019 |
| S-1/A · Registration statement, amended | Nov 8, 2019 |
All 15 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Nov 6, 2019 |
| CORRESP · Letter to the SEC | Oct 25, 2019 |
| S-1 · Registration statement | Oct 25, 2019 |
| UPLOAD · Letter from the SEC | Oct 9, 2019 |
| DRS · Draft registration statement | Sep 13, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed Nov 21, 2019
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 13.5M | 6.20M | 0 | |
| Cost of revenue | 41.6M | 34.3M | 1.11M | 1.31M | 566.0K | 21.0K | |
| Gross profit | -1.06M | -1.37M | -1.11M | -1.31M | -566.0K | -21.0K | |
| Research and development | 63.1M | 55.8M | 51.8M | 34.6M | 25.4M | 15.9M | 3.62M |
| Selling, general and administrative | 18.9M | 20.4M | 17.1M | 16.6M | 11.4M | 4.80M | 1.09M |
| Operating income | -83.9M | -76.2M | -68.9M | -51.2M | -36.8M | -20.7M | -4.71M |
| Depreciation and amortization | 1.06M | 1.37M | 1.11M | 975.0K | 377.0K | 21.0K | 4.71M |
| EBITDA | -82.8M | -74.9M | -67.8M | -50.2M | -36.5M | -20.7M | 0 |
| Interest expense | 13.5M | 6.20M | 11.0M | 0 | |||
| Income before tax | -75.8M | -71.3M | -64.5M | -37.7M | -30.6M | -6.44M | -4.99M |
| Income tax | 2.00K | 2.00K | -13.5M | -1.09M | 38.5K | -277 | |
| Net income | -75.8M | -71.3M | -64.5M | -37.7M | -30.6M | -31.7M | -4.99M |
| Earnings per share, basic | -3.95 | -4.89 | -6.18 | -10.33 | -2.69 | -5.17 | -28.34 |
| Earnings per share, diluted | -3.95 | -4.89 | -6.18 | -10.33 | -2.69 | -5.17 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 28.7M | 71.6M | 86.9M | 38.3M | 84.7M | 19.8M | 27.2M |
| Short-term investments | 100.2M | ||||||
| Receivables | 250.0K | 1.16M | 698.0K | 600.0K | |||
| Inventory | -548.0K | 95.5K | |||||
| Current assets | 34.6M | 75.8M | 88.9M | 41.7M | 87.8M | 20.7M | 27.2M |
| Property, plant and equipment | 102.0K | 1.88M | 2.73M | 3.57M | 3.69M | 693.0K | |
| Total assets | 35.8M | 79.9M | 94.9M | 48.4M | 93.7M | 23.4M | 27.2M |
| Accounts payable | 6.22M | 4.03M | 4.15M | 1.77M | 3.92M | 1.42M | 623.0K |
| Current liabilities | 13.2M | 15.2M | 12.4M | 7.07M | 8.02M | 4.01M | 1.99M |
| Long-term debt | 13.1M | ||||||
| Total debt | 1.24M | 1.81M | 2.79M | 3.65M | 2.88M | 1.62M | |
| Total liabilities | 31.6M | 18.2M | 16.5M | 12.4M | 24.1M | 14.6M | 6.11M |
| Shareholders' equity | 4.15M | 61.7M | 78.4M | 36.0M | 69.5M | -35.1M | 21.1M |
| Shares outstanding | 933.2K | 15.0M | 11.2M | 3.80M | 37.9M | 2.77M | 176.0K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -77.2M | -62.6M | -52.1M | -45.9M | -33.7M | -18.3M | -1.97M |
| Capital spending | -7.00K | -552.0K | -267.0K | -576.0K | -2.43M | -2.43M | -2.43M |
| Free cash flow | -77.2M | -63.2M | -52.3M | -46.4M | -36.1M | -18.3M | -1.97M |
| Cash from investing | 5.00K | -532.0K | -267.0K | -576.0K | -2.43M | 198.3K | -2.43M |
| Cash from financing | 34.2M | 47.9M | 101.0M | 55.0K | 101.0M | 11.3M | 29.1M |
| Share buybacks | 243.0K | 360.0K | -960.0K | 28.0K | 5.70M | ||
| Change in cash | -42.9M | -15.3M | 48.6M | -46.4M | 64.9M | -442.6K | 27.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
| 8-K · Current report | Nov 13, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 9, 2026 | Current report | SEC |
| 8-K · Current report | Nov 4, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 28, 2026 | Big-stake notice | SEC |
| SC TO-I/A | Oct 23, 2026 | Acquisition or disposal | SEC |
| DEF 14A · Proxy statement | Oct 20, 2026 | Meeting notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Oct 15, 2026 | Current report | SEC |
| S-3 · Registration statement | Oct 14, 2026 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Oct 9, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 7, 2026 | Current report | SEC |
| SC TO-I | Oct 7, 2026 | Acquisition or disposal | SEC |
| 8-K · Current report | Oct 5, 2026 | Meeting outcome | SEC |
| 8-K/A · Current report, amended | Oct 2, 2026 | Current report | SEC |
| 8-K/A · Current report, amended | Oct 1, 2026 | Current report | SEC |
| 8-K · Current report | Sep 28, 2026 | Management or board change | SEC |
| 25-NSE | Sep 24, 2026 | Other filings | SEC |
| DEF 14A · Proxy statement | Sep 4, 2026 | Meeting notice | SEC |
| 8-K · Current report | Aug 26, 2026 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Aug 24, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 14, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| D | Aug 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 3, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jul 31, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Jul 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 22, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 22, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 20, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 20, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 16, 2026 | Acquisition or disposal | SEC |
| 8-K · Current report | Jul 16, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 10, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Jun 15, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jun 15, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jun 15, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jun 9, 2026 | Current report | SEC |
| 8-K · Current report | Jun 1, 2026 | Current report | SEC |
| 8-K · Current report | May 21, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 8, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 8, 2026 | Big-stake notice | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 30, 2026 | Results | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 25, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 18, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 11, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 26, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 8, 2026 | Current report | SEC |
| 8-K · Current report | Jan 7, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 2, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 2, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 23, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 19, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Sep 19, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Sep 18, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 6, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 11, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 9, 2025 | Management or board change | SEC |
| 8-K · Current report | Jul 7, 2025 | Current report | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 3, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 16, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | May 19, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 19, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 19, 2025 | Meeting notice | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Mar 27, 2025 | Other filings | SEC |
| 424B5 · Prospectus | Mar 26, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 24, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 21, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 19, 2025 | Material contract | SEC |
| S-3 · Registration statement | Mar 19, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 28, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 11, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 8, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 12, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 12, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 15, 2024 | Current report | SEC |
| 4 · Change in ownership | Sep 12, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 12, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 12, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| S-8 POS | Jun 7, 2024 | Offer document | SEC |
| S-8 POS | Jun 7, 2024 | Offer document | SEC |
| S-8 POS | Jun 7, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Jun 7, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | May 3, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 22, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 22, 2024 | Meeting notice | SEC |
| SC 13G · Big-stake notice | Mar 27, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 12, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 12, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 6, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 5, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 4, 2024 | Results | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 12, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 12, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| 424B5 · Prospectus | Feb 6, 2024 | Offer document | SEC |
| 8-K · Current report | Feb 6, 2024 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 5, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 2, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 4, 2024 | Current report | SEC |
| 8-K · Current report | Jan 2, 2024 | Current report | SEC |
| 8-K · Current report | Dec 20, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | Nov 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2023 | Insider trade | SEC |
| DEF 14A · Proxy statement | Nov 20, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Nov 9, 2023 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 4 · Change in ownership | Nov 2, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 2, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 1, 2023 | Management or board change | SEC |
| 8-K · Current report | Oct 20, 2023 | Current report | SEC |
| 4 · Change in ownership | Oct 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2023 | Insider trade | SEC |
This page holds 200 of 489 filings. Open Filings
Cap table
Built by 6ix from Jasper Therapeutics, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 1,109,152
- Fully diluted
- 13,582,665
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 1,109,152 | Nov 6, 2026 |
| Warrants | 12,473,513 | Sep 22, 2025 |
Warrants and options
| Lot |
|---|
| Warrants · US$2.92 · expire about Sep 2029 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 1,109,152 |
| Nov 6, 2026 | |
| Nov 4, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Thomas Wiggans Other companies: Pacira BioSciences, Inc. (Director · Since at least Jun 9, 2026); Annexon, Inc. (Director · Since at least Jul 23, 2020); Pardes Biosciences Inc (Chief Executive Officer, Director · Mar 1, 2022 – Aug 31, 2023 · Past); Forma Therapeutics Holdings Inc (Director · Sep 7, 2020 – Oct 14, 2022 · Past); Somaxon Pharmaceuticals Inc (Director · Jun 11, 2008 – Jul 2, 2012 · Past); Sangamo Therapeutics, Inc. (Director · Jun 4, 2008 – Jun 1, 2011 · Past); Onyx Pharmaceuticals Inc (Director · Aug 29, 2007 – Oct 1, 2013 · Past) | Chairman of the Board · Since at least Nov 1, 2023 |
| William Lis Other companies: Zai Lab Ltd. (Board Member · Since at least Jan 1, 2021); Eidos Therapeutics Inc (Director · Dec 4, 2018 – Jan 26, 2021 · Past); Portola Pharmaceuticals Inc (Chief Executive Officer, Director · May 21, 2013 – Jul 28, 2018 · Past) | Director · Sep 24, 2021 – Oct 13, 2023 · Past |
| Kurt von Emster Other companies: Vera Therapeutics, Inc. (Director · May 13, 2021 – May 17, 2021 · Past); Vaxcyte, Inc. (Director · Jun 11, 2020 – Jun 2, 2021 · Past) | Board Member · Since at least Sep 24, 2021 |
| Greg Keenan Other companies: Aurinia Pharmaceuticals Inc (SVP, Chief Medical Officer · Since at least Nov 7, 2024) | Chief Medical Officer · Since at least Jul 16, 2026 |
| Abby Kennedy | Vice President, Clinical Operations · Since at least Nov 4, 2026 |
| Greg Keenan | Chief Medical Officer · Since at least Oct 15, 2026 |
| Helen Fu | Vice President, Corporate Portfolio and Project Management · Since at least Nov 5, 2026 |
| Jeet Mahal | Chief Executive Officer · Since at least Sep 15, 2026 |
| Judith Shizuru | Director · Since at least Sep 24, 2021 |
| Kenneth F Clifford | Chief Financial Officer · Nov 19, 2019 – Jan 3, 2020 · Past |
All 22 people
| Person | Seat |
|---|---|
| Kevin N Heller | See Remarks · Sep 24, 2021 – Mar 21, 2022 · Past |
| Lisa Pitt | Senior Vice President, Regulatory Affairs · Since at least Sep 15, 2026 |
| Mark Camarena | Vice President, Information Technology and Facilities · Since at least Nov 5, 2026 |
| Matt Ford | Senior Vice President, Human Resources · Since at least Nov 4, 2026 |
| Matthew Ros | Chief Operating Officer · Since at least Jul 16, 2026 |
| Patrick Crutcher | Board Member · Since at least Jul 16, 2026 |
| Rick Ruiz | Vice President, Finance · Since at least Nov 4, 2026 |
| Ron Martell | President, CEO and Director, Director · Since at least Oct 12, 2023 |
| Shiguang Liu | Vice President, Clinical Development · Since at least Sep 15, 2026 |
| Svetlana Lucas | Board Member · Since at least Jul 16, 2026 |
| Vishal Kapoor | Director · Since at least Jan 6, 2020 |
| Wenru Song | Executive Vice President and Head of R&D · Since at least Jul 16, 2026 |
Log in to ask 6ix AI your own questions about Jasper Therapeutics, Inc.